Alpha Cognition Inc (ACOG)
Alpha Cognition Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Grapevine, TX, US. The stock last traded at $9.02, up 1.52% on the session, giving a market capitalisation of $140.1M. On trailing twelve-month figures it carries a trailing P/E of -6.72, a net margin of -232.2%. Its beta of 2.23 implies it has historically moved more than the broad market.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc is most often compared with the following Healthcare names: